← Back to Search

N/A

CellFX Treated Wart for Warts

N/A
Waitlist Available
Research Sponsored by Pulse Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60-days post-last cellfx treatment
Awards & highlights

Summary

This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.

Eligible Conditions
  • Warts
  • Warts Hand Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60-days post-last cellfx treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60-days post-last cellfx treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Verrucae Cleared
Secondary study objectives
Subject Satisfaction

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CellFX Treated WartExperimental Treatment1 Intervention
Treated wart with CellFX device intervention
Group II: Non-treated WartActive Control1 Intervention
Control wart for each enrolled subject without intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CellFX Device
2019
N/A
~70

Find a Location

Who is running the clinical trial?

Pulse Biosciences, Inc.Lead Sponsor
9 Previous Clinical Trials
730 Total Patients Enrolled
1 Trials studying Warts
150 Patients Enrolled for Warts
Richard Nuccitelli, PhDStudy ChairPulse Biosciences, Inc.
3 Previous Clinical Trials
282 Total Patients Enrolled
1 Trials studying Warts
150 Patients Enrolled for Warts
~10 spots leftby Sep 2025